Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Capital Employed: 2022-2025

Historic Return on Capital Employed for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to -0.34%.

  • Taysha Gene Therapies' Return on Capital Employed rose 20.00% to -0.34% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.34%, marking a year-over-year increase of 20.00%. This contributed to the annual value of -0.65% for FY2024, which is 1.00% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Return on Capital Employed of -0.34% as of Q3 2025, which was up 22.82% from -0.45% recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Return on Capital Employed registered a high of 2.64% during Q3 2023, and its lowest value of -2.92% during Q2 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.55% (2024), whereas its average is -0.62%.
  • As far as peak fluctuations go, Taysha Gene Therapies' Return on Capital Employed spiked by 241bps in 2023, and later crashed by 318bps in 2024.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Return on Capital Employed stood at -2.90% in 2022, then soared by 241bps to -0.49% in 2023, then declined by 14bps to -0.63% in 2024, then grew by 20bps to -0.34% in 2025.
  • Its Return on Capital Employed was -0.34% in Q3 2025, compared to -0.45% in Q2 2025 and -0.70% in Q1 2025.